Cargando…
RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial
BACKGROUND: Glypican-3 (GPC3) is a well-characterized hepatocellular carcinoma (HCC)-associated antigen and a promising target for HCC treatment. CT017 CAR T cells were engineered to co-express CAR-GPC3 and runt-related transcription factor 3 (RUNX3), which triggers CD8(+) T-cell infiltration into t...
Autores principales: | Fu, Qihan, Zheng, Yi, Fang, Weijia, Zhao, Qingwei, Zhao, Peng, Liu, Lulu, Zhai, You, Tong, Zhou, Zhang, Hangyu, Lin, Meihua, Zhu, Xudong, Wang, Huamao, Wang, Yumeng, Liu, Zhen, Yuan, Daijing, Bao, Xuanwen, Gao, Wanwan, Dai, Xiaomeng, Li, Zonghai, Liang, Tingbo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480529/ https://www.ncbi.nlm.nih.gov/pubmed/37680942 http://dx.doi.org/10.1016/j.eclinm.2023.102175 |
Ejemplares similares
-
Oxaliplatin plus irinotecan vs irinotecan as second-line treatment in pancreatic cancer patients: a randomized–controlled open-label Phase II study
por: Zhang, Hangyu, et al.
Publicado: (2023) -
Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma
por: Dai, Xiaomeng, et al.
Publicado: (2021) -
Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy
por: Bao, Xuanwen, et al.
Publicado: (2020) -
Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report
por: Sun, Hongwei, et al.
Publicado: (2022) -
Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma
por: Li, Kesang, et al.
Publicado: (2015)